ArticleVirchows Archiv : an international journal of pathology2026
Sarcomatous transformation of an astrocytoma IDH-mutant following radiotherapy.
Article in Virchows Archiv : an international journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report a case of astrocytoma IDH-mutant grade 2, which progressed to an IDH-mutant sarcomatous neoplasia after multiple treatments, including radiotherapy. The last recurrence histologically exhibited sarcomatous morphology, characterized by spindle cells, necrosis, and brisk mitotic activity. The neoplastic cells were negative for GFAP and OLIG2, positive for IDH1p.R132H and P53, with loss of ATRX expression and focal loss of H3 K27me3. Focal immunoreactivity for smooth muscle actin, desmin, and YAP1 was also observed. DNA methylation profiling yielded subthreshold scores suggestive of oligosarcoma, IDH-mutant, using the Heidelberg classifier and undifferentiated sarcoma using the sarcoma classifier. The Bethesda classifier did not provide a confident match. Nevertheless, UMAP analysis showed proximity of the recurrent tumor to the oligosarcoma methylation cluster. Overall, the sarcomatous recurrent neoplasia retained immunophenotypic and molecular features of astrocytomas IDH-mutant, while exhibiting an epigenetic divergent profile. This case expands the spectrum of sarcomatous progression in IDH-mutant diffuse gliomas and raises the possibility that astrocytomas, similar to oligodendrogliomas, may rarely undergo sarcomatous transformation. Additional cases and integrated molecular studies will be required to determine whether such tumors represent a distinct biological subgroup.
Indexed as
Identifiers
42467228What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.